Completed PHASE2 INTERVENTIONAL 3-arm NCT02220803

A Short Term Open, Randomized Cross-over Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension and Vascular Dysfunction

A Short Term Open, Randomized Cross Over Trial Trial Exploring the Effect of Carbonic Anhydrase Inhibition by Acetazolamide on Sleep Apnea Associated Hypertension

Sponsor: Göteborg University

Conditions Blood Pressure Hypertension Obstructive Sleep Apnea Sleep-Disordered Breathing

Interventions Acetazolamide nasal Continuous Positive Airway Pressure (nCPAP)

Updated 5 times since 2017 Last updated: Aug 15, 2016 Started: Mar 31, 2014 Primary completion: Aug 31, 2016 Completion: Aug 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02220803, this PHASE2 trial focuses on Blood Pressure and Hypertension and remains completed. Sponsored by Göteborg University, it has been updated 5 times since 2014, reflecting limited change activity. This study contributes longitudinal data to the cardiovascular research landscape.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Mar 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Göteborg University

Data source: Göteborg University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gothenburg, Sweden